Skip to content

Annexon ANNX Operating Cash Flow

Operating Cash Flow at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.08B+3.2%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-$28.86M-4.4%
Omeros logo
OmerosOMER
-$14.51M+59.5%
Vor Biopharma logo
Vor BiopharmaVOR
-$38.25M-23.1%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$46.05M-6.7%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$44.3M+9.7%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's operating cash flow?
Annexon (ANNX) reported operating cash flow of -$46.8M in Q1 2026.
How has Annexon's operating cash flow changed year-over-year?
Annexon's operating cash flow increased by 6.5% year-over-year, from -$50.06M to -$46.8M.
What is the long-term trend for Annexon's operating cash flow?
Over 4 years (2021 to 2025), Annexon's operating cash flow has grown at a 15.1% compound annual growth rate (CAGR), from -$106.11M to -$186.36M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.